(SRDX) SurModics - Ratings and Ratios
Coating Technologies, Diagnostic Components, Medical Devices
SRDX EPS (Earnings per Share)
SRDX Revenue
Description: SRDX SurModics
Surmodics Inc (NASDAQ:SRDX) is a company that specializes in providing performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic tests. The company operates through two main segments: Medical Device and In Vitro Diagnostics (IVD).
The Medical Device segment is a key driver of the companys growth, providing surface modification coating technologies and drug-delivery coating technologies to enhance the performance of medical devices. Surmodics also manufactures vascular intervention medical devices, including drug-coated balloons and mechanical thrombectomy devices, which are used in various medical applications.
From a financial perspective, Surmodics has a market capitalization of $414.82M USD, indicating a relatively small-cap company. The companys forward P/E ratio is 208.33, suggesting high growth expectations. However, the Return on Equity (RoE) is -17.31%, indicating that the company is currently unprofitable. To evaluate the companys financial health, we can also consider other KPIs such as Revenue Growth Rate, Gross Margin, and Operating Cash Flow. For instance, a high Revenue Growth Rate could indicate a strong demand for Surmodics products, while a stable Gross Margin could suggest a competitive advantage. Additionally, a positive Operating Cash Flow would indicate that the company is generating sufficient cash to meet its financial obligations.
To further analyze Surmodics performance, we can examine its revenue segmentation and product pipeline. The companys IVD segment offers a range of products, including protein stabilizers and surface coatings, which are used in diagnostic and biomedical research markets. By evaluating the revenue contribution from each segment and product, we can gain insights into the companys diversification and potential areas of growth. Furthermore, an analysis of the companys research and development (R&D) expenses and pipeline products can provide insights into its innovation capabilities and potential future growth drivers.
SRDX Stock Overview
| Market Cap in USD | 470m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1998-03-04 |
SRDX Stock Ratings
| Growth Rating | -31.6% |
| Fundamental | 31.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -31.4% |
| Analyst Rating | 3.0 of 5 |
SRDX Dividends
Currently no dividends paidSRDX Growth Ratios
| Growth Correlation 3m | 58.7% |
| Growth Correlation 12m | -60.8% |
| Growth Correlation 5y | -56.8% |
| CAGR 5y | 2.70% |
| CAGR/Max DD 3y | 0.05 |
| CAGR/Mean DD 3y | 0.17 |
| Sharpe Ratio 12m | -0.40 |
| Alpha | 0.00 |
| Beta | 0.959 |
| Volatility | 33.48% |
| Current Volume | 155.9k |
| Average Volume 20d | 162.4k |
| Stop Loss | 30.7 (-3.8%) |
| Signal | -0.40 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-17.6m TTM) > 0 and > 6% of Revenue (6% = 7.25m TTM) |
| FCFTA -0.02 (>2.0%) and ΔFCFTA -6.19pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 46.82% (prev 49.79%; Δ -2.98pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.01 (>3.0%) and CFO -1.88m > Net Income -17.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.91 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (14.3m) change vs 12m ago 0.78% (target <= -2.0% for YES) |
| Gross Margin 73.09% (prev 57.38%; Δ 15.71pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 69.58% (prev 68.10%; Δ 1.48pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -4.61 (EBITDA TTM -8.23m / Interest Expense TTM 3.49m) >= 6 (WARN >= 3) |
Altman Z'' 3.88
| (A) 0.33 = (Total Current Assets 76.0m - Total Current Liabilities 19.4m) / Total Assets 169.8m |
| (B) 0.36 = Retained Earnings (Balance) 61.5m / Total Assets 169.8m |
| (C) -0.09 = EBIT TTM -16.1m / Avg Total Assets 173.6m |
| (D) 1.08 = Book Value of Equity 63.4m / Total Liabilities 58.5m |
| Total Rating: 3.88 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 31.01
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -0.69% = -0.35 |
| 3. FCF Margin -2.69% = -1.01 |
| 4. Debt/Equity 0.28 = 2.46 |
| 5. Debt/Ebitda -3.73 = -2.50 |
| 6. ROIC - WACC (= -20.37)% = -12.50 |
| 7. RoE -15.59% = -2.50 |
| 8. Rev. Trend 7.69% = 0.58 |
| 9. EPS Trend -3.48% = -0.17 |
What is the price of SRDX shares?
Over the past week, the price has changed by -0.67%, over one month by -13.51%, over three months by +9.83% and over the past year by -18.73%.
Is SurModics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SRDX is around 29.39 USD . This means that SRDX is currently overvalued and has a potential downside of -7.9%.
Is SRDX a buy, sell or hold?
- Strong Buy: 0
- Buy: 0
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the SRDX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 43 | 34.8% |
| Analysts Target Price | 43 | 34.8% |
| ValueRay Target Price | 32.9 | 3.2% |
Last update: 2025-09-11 04:50
SRDX Fundamental Data Overview
CCE Cash And Equivalents = 32.7m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 208.3333
P/S = 3.888
P/B = 4.2196
P/EG = 3.8952
Beta = 1.37
Revenue TTM = 120.8m USD
EBIT TTM = -16.1m USD
EBITDA TTM = -8.23m USD
Long Term Debt = 29.7m USD (from longTermDebt, last quarter)
Short Term Debt = 1.02m USD (from shortTermDebt, last quarter)
Debt = 30.7m USD (Calculated: Short Term 1.02m + Long Term 29.7m)
Net Debt = -26.3m USD (from netDebt column, last quarter)
Enterprise Value = 467.6m USD (469.7m + Debt 30.7m - CCE 32.7m)
Interest Coverage Ratio = -4.61 (Ebit TTM -16.1m / Interest Expense TTM 3.49m)
FCF Yield = -0.69% (FCF TTM -3.24m / Enterprise Value 467.6m)
FCF Margin = -2.69% (FCF TTM -3.24m / Revenue TTM 120.8m)
Net Margin = -14.59% (Net Income TTM -17.6m / Revenue TTM 120.8m)
Gross Margin = 73.09% ((Revenue TTM 120.8m - Cost of Revenue TTM 32.5m) / Revenue TTM)
Tobins Q-Ratio = 7.37 (Enterprise Value 467.6m / Book Value Of Equity 63.4m)
Interest Expense / Debt = 2.82% (Interest Expense 865.0k / Debt 30.7m)
Taxrate = 21.0% (US default)
NOPAT = -16.1m (EBIT -16.1m, no tax applied on loss)
Current Ratio = 3.91 (Total Current Assets 76.0m / Total Current Liabilities 19.4m)
Debt / Equity = 0.28 (Debt 30.7m / last Quarter total Stockholder Equity 111.3m)
Debt / EBITDA = -3.73 (Net Debt -26.3m / EBITDA -8.23m)
Debt / FCF = -9.46 (Debt 30.7m / FCF TTM -3.24m)
Total Stockholder Equity = 113.1m (last 4 quarters mean)
RoA = -10.38% (Net Income -17.6m, Total Assets 169.8m )
RoE = -15.59% (Net Income TTM -17.6m / Total Stockholder Equity 113.1m)
RoCE = -11.27% (Ebit -16.1m / (Equity 113.1m + L.T.Debt 29.7m))
RoIC = -11.27% (NOPAT -16.1m / Invested Capital 142.7m)
WACC = 9.10% (E(469.7m)/V(500.4m) * Re(9.55%)) + (D(30.7m)/V(500.4m) * Rd(2.82%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 93.94 | Cagr: 0.22%
Discount Rate = 9.55% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -3.24m)
EPS Correlation: -3.48 | EPS CAGR: -17.60% | SUE: 0.29 | # QB: 0
Revenue Correlation: 7.69 | Revenue CAGR: 4.80% | SUE: 0.26 | # QB: 0
Additional Sources for SRDX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle